Advertisement

Archives of Pharmacal Research

, Volume 18, Issue 5, pp 340–345 | Cite as

Bioequivalence study of nabumetone tablets in man

  • Young-Joo Lee
  • Eun-Ju Jang
  • Jeong-Uk Lee
  • Yong-Hae Han
  • Suk-Jae Chung
  • Min-Hwa Lee
  • Chang-Koo Shim
Research Articles

Abstract

A nabumetone tablet in development (NabutonR) was tested for its bioequivalence to the reference tablet (UnitonR). Seventeen healthy Korean male subjects participated in this study. Each subject received a 1-g dose of nabumetone (2 tablets each) in an unbalanced, randomized, two-way crossover investigation. Serum concentrations of 6-methoxy-2-naphthylacetic acid (6-MNA), a major metabolite of nabumetone, were measured over 120 hr interval by a high-performance liquid chromatography. The maximum serum concentration (Cmax) and time to reach the maximum concentration (Tmax) were read directly, but area under the serum concentration time curve from time 0 to 120 hr (AUC) and mean residence time (MRT) of 6-MNA were calculated from the serum 6-MNA concentration-time curves. The serum curves showed multiple peaks of 6-MNA in most subjects, and the Cmax and Tmax were read from the highest serum peaks. Calculated bioavailability parameters for test and reference tablets were 1498.6∶1377.9 μg·hr/ml for AUC; 25.2∶23.1 μg/ml for Cmax; 11.8∶16.4 hr for Tmax and 42.6∶43.8 hr for MRT, respectively. The pairedt-test revealed no significant differences in all the parameters between the two tablets. Analysis of variance (ANOVA) revealed no significant differences between groups and formulations in all the parameters (Cmax, Tmax, AUC and MRT) indicating the crossover design of the experiment was properly performed. But significant differences (p<0.05) between subject/groups and periods were found for all the parameters indicating substantial intersubject and interperiodic variations for these parameters.

Key words

Nabumetone 6-Methoxy-2-naphthylacetic acid (6-MNA) Bioquivalence AUC Cmax, Tmax, MRT Multiple peaks ANOVA 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References Cited

  1. Concise Statistical Tables, Japan Association of Standardization. 1976, pp 50–51.Google Scholar
  2. Daigneault, E. A., Ferslew, K. E. and Stanton, P., Bioequivalence study of nabumetone: tablet versus suspension.Am. J. Medicine, 83, 11–14 (1987).CrossRefGoogle Scholar
  3. Food and Drug Administration (FDA). Division of Biopharmaceutics.Bioavailability Protocol Guideline for ANDA and NDA Submission, 1977.Google Scholar
  4. Food and Drug Administration (FDA). Report by the bioequivalence task force on recommendation from the bioequivalence hearing conducted by the FDA, 29, September, 1986-1, Octerber, 1988.Google Scholar
  5. Friedel, H. A. and Todd, P. A., Nabumetone—a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic disease.Drugs, 35, 504–524, 1988.PubMedCrossRefGoogle Scholar
  6. Haddock, R. E., Teffery, D. J., Lloyd, J. A. and Thawley, A. R., Metabolism of nabumetone (BRL 14777) by various species including man.Xenobiotica 14, 327–337, 1984.PubMedCrossRefGoogle Scholar
  7. Jang, E. J., Lee, Y. J., Park, M. G. S. and Shim, C. K., HPLC assay of 6-methoxy-2-naphthylacetic acid, a major metabolite of nabumetone, in human serum.Anal. Lett. 28, 2379–2389, 1995.Google Scholar
  8. Korean Guidelines for Bioequivalence Test. National Institute of Safety Research, Korea, 1988.Google Scholar
  9. Mangan, F. R., Flack, J. D., and Jackson, D., Preclinical overview of nabumetone pharmacology, bioavailability, metabolism, and toxicology.Am. J. Medicine, 83, 6–10, 1987.CrossRefGoogle Scholar
  10. Ogata, H. and Ejima, A.,Bioavailability and Bioequivalence Test of Drugs, Yakugyo Jiho Co., Ltd., Tokyo, Japan, 1989, pp. 70–72.Google Scholar
  11. Schuirmann, D. J., Use of logarithmic transformation for analysis of bioavailability/bioequivalence data. Paper presented at the DIA-Workshop on Bioavailability/Bioequivalence: Pharmacokinetic and Statistical Considerations, Bethesda, Md., August 5–7, 1991, Audio Transcripts Ltd. Alexandria, 1991.Google Scholar
  12. Shim, C. K., Report on bioequivalence test of NabutonR tablet. Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, 1994.Google Scholar
  13. Shim, C. K. and Hong, J. S., Inter- and intrasubject variations of ranitidine pharmacokinetics after oral administration to normal male subjects.J. Pharm. Sci., 78, 990–994, 1989.PubMedCrossRefGoogle Scholar
  14. Shim, C. K. and Jung, B. H., Inter- and intrasubject variations of multiple saliva peaks of acetaminophen after oral administration of tablets.Int. J. Pharm., 82, 233–237, 1992a.CrossRefGoogle Scholar
  15. Shim, C. K. and Jung, B. H., Noncontribution of enterohepatic recycling to multiple plasma peaks of acetaminophen after oral administration to rats.Int. J. Pharm., 83, 257–262, 1992b.CrossRefGoogle Scholar
  16. Shim, C. K. and Suh, M. K., Multiple plasma peaks of acetaminophen and ranitidine after simultaneous oral administration to rats.Arch. Pharm. Res., 15, 246–250, 1992.CrossRefGoogle Scholar
  17. Steinijans, V. W., Hauschke, D. and Jonkman, J. H. G., Controversies in bioequivalence studies.Clin. Pharmacokin., 22, 247–253, 1992.CrossRefGoogle Scholar
  18. Tsuchiya, K. Statistical analysis for bioequivalence studies. InHuman Studies for Healthy Subjects, Tsunoo, M. (Ed.), Seishi Shoin, 1985, pp. 210–225.Google Scholar
  19. Von, Schrader, H. W., Buscher, G., Dierdorf, D., Mugge, H. and Wolf, D., Nabumetone—a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses.Int. J. Clin. Pharmacol. Therap. Toxicol, 21, 311–321, 1983.Google Scholar

Copyright information

© The Pharmaceutical Society of Korea 1995

Authors and Affiliations

  • Young-Joo Lee
    • 1
  • Eun-Ju Jang
    • 1
  • Jeong-Uk Lee
    • 1
  • Yong-Hae Han
    • 1
  • Suk-Jae Chung
    • 1
  • Min-Hwa Lee
    • 1
  • Chang-Koo Shim
    • 1
  1. 1.Department of Pharmaceutics, College of PharmacySeoul National UniversitySeoulKorea

Personalised recommendations